Latest Press Releases

10 June 2025

ATB Therapeutics Announces Appointment of Dr. Torsten Dreier as Chief Development Officer and Opening of New R&D Hub in Gent

18 November 2024

In October 2024 ATB Therapeutics Raises €54 Million Series A Financing
View all press releases

A pioneering biotechnology company dedicated to novel antibody therapies for oncology and auto-immune disease.

Terms & Conditions|Privacy Policy
© 2020-2026 ATB Therapeutics.
All rights reserved.

Contact

atbtherapeutics

Novalis Science Park,
Rue de la Science, 8
6900 Aye, Belgium

 

VIB,
Suzanne Tassierstraat 1
9052 Ghent, Belgium

Contact

atbtherapeutics

Novalis Science Park,
Rue de la Science, 8
6900 Aye, Belgium

 

VIB,
Suzanne Tassierstraat 1
9052 Ghent, Belgium

info@atbtherapeutics.com
Terms & Conditions|Privacy Policy
© 2020-2026 ATB Therapeutics. <br>All rights reserved.
Website by